Results from the Iressa® Pan-Asia Study (10) clinical trial indicated that, in Asian populations, patients with EGFR mutations were more responsive to chemotherapy than patients with wild-type EGFR. Patients with lung cancer with low expression of ERCC1 and RRM1 are more responsive to gemcitabine- and platinum-based chemotherapy, respectively (11,12). Here, EGFR is linked to lung cancer.